U.S. markets closed
  • S&P Futures

    3,792.75
    +2.25 (+0.06%)
     
  • Dow Futures

    30,822.00
    -6.00 (-0.02%)
     
  • Nasdaq Futures

    13,026.25
    +40.75 (+0.31%)
     
  • Russell 2000 Futures

    2,140.40
    -6.90 (-0.32%)
     
  • Crude Oil

    53.12
    +0.14 (+0.26%)
     
  • Gold

    1,845.30
    +5.10 (+0.28%)
     
  • Silver

    25.45
    +0.14 (+0.53%)
     
  • EUR/USD

    1.2143
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.0920
    -0.0050 (-0.46%)
     
  • Vix

    23.24
    -1.10 (-4.52%)
     
  • GBP/USD

    1.3642
    +0.0008 (+0.06%)
     
  • USD/JPY

    103.8380
    -0.0540 (-0.05%)
     
  • BTC-USD

    36,289.76
    +134.11 (+0.37%)
     
  • CMC Crypto 200

    720.25
    +5.06 (+0.71%)
     
  • FTSE 100

    6,712.95
    -7.70 (-0.11%)
     
  • Nikkei 225

    28,608.56
    -24.90 (-0.09%)
     

Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

·1 min read

EMERYVILLE, Calif., Jan. 6, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2021 Conference being held January 11-14, 2021.

(PRNewsfoto/Dynavax Technologies)
(PRNewsfoto/Dynavax Technologies)

The on demand presentation will be available, beginning Monday, January 11, 2021 at 6:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt
narndt@dynavax.com
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2021-conference-301202218.html

SOURCE Dynavax Technologies